{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:15:24Z","timestamp":1761488124649,"version":"3.35.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T00:00:00Z","timestamp":1223596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The delta opioid peptide (DOP) receptor has been proposed as a target in the symptomatic therapy of Parkinson\u2019s disease. However, the circuitry underlying the antiparkinsonian action of DOP receptor agonists and their site of action have never been adequately investigated. Systemic administration of the DOP receptor agonist (+)\u20104\u2010[(\u03b1R)\u2010\u03b1\u2010(2<jats:italic>S<\/jats:italic>,5<jats:italic>R<\/jats:italic>)\u2010allyl\u20102,5\u2010dimethyl\u20101\u2010piperazinyl)\u20103\u2010methoxy\u2010benzyl]\u2010<jats:italic>N\u2010N<\/jats:italic>\u2010diethylbenzamide (SNC\u201080) attenuated akinesia\/bradykinesia and improved motor activity in 6\u2010hydroxydopamine hemilesioned rats. Opposite effects were produced by the selective DOP receptor antagonist naltrindole (NTD), suggesting that endogenous enkephalins tonically sustain movement under parkinsonian conditions. Microdialysis revealed that SNC\u201080 reduced GABA release in globus pallidus (GP) while NTD elevated it. Moreover, SNC\u201080 reduced GABA and glutamate release in substantia nigra reticulata (SNr) whereas NTD reduced GABA without affecting glutamate release. The bar test coupled to microdialysis showed that perfusion with NTD in SNr but not GP or striatum prevented the antiakinetic effect of systemic SNC\u201080 and its neurochemical correlates. Consistently, microinjections of SNC\u201080 into SNr or bicuculline in GP attenuated parkinsonian\u2010like symptoms while SNC\u201080 microinjections in GP or striatum were ineffective. This study demonstrates that nigral DOP receptors mediate antiparkinsonian actions of SNC\u201080 and challenges the common view that DOP receptor agonists solely attenuate parkinsonism via pallidal mechanisms.<\/jats:p>","DOI":"10.1111\/j.1471-4159.2008.05727.x","type":"journal-article","created":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T06:48:33Z","timestamp":1223621313000},"page":"1647-1659","source":"Crossref","is-referenced-by-count":25,"title":["Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6\u2010hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism"],"prefix":"10.1111","volume":"107","author":[{"given":"Omar S.","family":"Mabrouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Volta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Morari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)90261-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.06.038"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.037655"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0022-3565(25)09569-2","article-title":"SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist","volume":"273","author":"Bilsky E. J.","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.01.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(90)90110-V"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)90214-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(85)90121-6"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90062-1"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.901800310"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00784-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00221-003-1638-7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)91217-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2147780"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-595X(83)80028-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(81)90188-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21163"},{"key":"e_1_2_8_19_1","first-page":"261","article-title":"\u03b4\u2010opioid receptor agonists as a therapeutic approach in Parkinson\u2019s disease","volume":"13","author":"Hill M. P.","year":"2000","journal-title":"Drug News Perspect."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7763"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00209-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(83)90838-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(72)90086-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90464-2"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.11-06-01565.1991"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1994.1007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0891-0618(93)90010-2"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01169.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0987-04.2004"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2546-05.2005"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4346-06.2007"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0022-3565(25)21002-3","article-title":"Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists","volume":"246","author":"Matsumoto R. R.","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90947-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-19-07471.1997"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-547620-1.50007-2"},{"key":"e_1_2_8_36_1","first-page":"15","article-title":"Dopamine\u2010dependent behavioural stimulation by non\u2010peptide delta opioids BW 373U86 and SNC 80\u2003:\u20033. Facilitation of D1 and D2 responses in unilaterally 6\u2010hydroxydopamine\u2010lesioned rats","volume":"9","author":"Pinna A.","year":"1998","journal-title":"Behav. Pharmacol."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00137-0"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90502-X"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025113818854"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90872-9"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1990.tb05428.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(96)01162-6"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1037\/0735-7044.102.5.748"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(79)90003-7"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01010.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020738304036"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-12-04796.1999"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(70)90187-3"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.073940"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9827"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.11.006"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2008.05727.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2008.05727.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T17:10:53Z","timestamp":1738429853000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2008.05727.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,24]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1471-4159.2008.05727.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05727.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"type":"print","value":"0022-3042"},{"type":"electronic","value":"1471-4159"}],"subject":[],"published":{"date-parts":[[2008,11,24]]}}}